| Autor: |
Zarin D; Retired, Chevy Chase, MD., Wittes JT; Wittes LLC, Washington, DC., Fleming TR; University of Washington, Seattle., Rockhold F; Duke University Medical Center, Durham, NC., Ellenberg S; University of Pennsylvania, Philadelphia., DeMets DL; University of Wisconsin-Madison, Madison. |
| Jazyk: |
angličtina |
| Zdroj: |
NEJM evidence [NEJM Evid] 2024 Sep; Vol. 3 (9), pp. EVIDctw2400058. Date of Electronic Publication: 2024 Aug 27. |
| DOI: |
10.1056/EVIDctw2400058 |
| Abstrakt: |
AbstractClinical trials investigating novel or high-risk interventions often use data monitoring committees (DMCs) to ensure that the participants' best interests are safeguarded. The typical DMC charter describes procedures by which the DMC operates, including important details concerning organizational structure, membership, meeting frequency, statistical monitoring guidelines, and contents of DMC reports for interim review. These charters, however, are not routinely publicly available; in some cases, their access could be important to the interpretation of trial results. We recommend including DMC charters for such trials in ClinicalTrials.gov at the time of trial completion; trial protocols, informed consent documents, and statistical analysis plans are already available in this repository. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
